ChronTech receives a six months' extension of its option to buy back in ChronSeal®


ChronTech receives a six months' extension of its option to buy back in
ChronSeal® 

As a consequence of that the results of the ChronSeal® study will not be made
public until May 27th Kringle Inc. in Japan has given ChronTech Pharma a six
months' extension, i.e. until the 31st of December 2010, of its option to buy
back in ownership of the ChronSeal®.



For more information, please contact:
Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28, 
E-mail: anders.vahlne@ki.se



About ChronTech
ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs
against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic
infections with jaundice causing viruses which can lead to liver cirrhosis and
liver cancer. ChronTech has also developed and further develops a patent pending
new type of injection needle for a more effective uptake of DNA vaccines.
ChronTech also have part ownership in the wound healing therapy ChronSeal®, and
in the new platform technology RAS®. The ChronTech share is admitted to trade on
First North. Remium AB is Certified Adviser for ChronTech. For more information,
please visit: www.chrontech.se

In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take precedence.

Attachments

05112527.pdf
GlobeNewswire